Medicrea Announces 2016 Third-Quarter Sales

The Medicrea Group (Alternext Paris: FR0004178572 – ALMED), worldwide leader pioneering the development and manufacture of personalized analytical services and implant solutions for the treatment of complex spinal conditions, announced its sales for the 3rd quarter ending September 30, 2016.

Sales reached a total of €6.8 million over the third quarter, down 3%
compared to the same quarter of 2015, due to a temporary decrease in
activity in Europe.
Year-to-date 2016, Medicrea sales have increased by 3% thanks to its
priority markets, the United States (+9%) and France (+13%) where the
adoption of UNiD™ patient-specific technology is continuing with
more than 100 surgeons utilizing this service and the significant 1,000
UNiD™ surgery milestone anticipated within the next month.
Outlook:
Medicrea is currently participating in the Eurospine congress in Berlin
from the 5^th to the 7^th of October and will be
present at the world’s largest convention for spine specialists
organized by the NASS (North American Spine Society) in Boston from the
26^th to the 29^th of October. During this event,
the company is expected to announce a major development related to the
UNiD™ services and personalized treatment modalities.
From early September, the Group has undertaken the relocation of
production facilities and office headquarters to its new site near Lyon,
gathering all the activities in a single infrastructure to improve
productivity and optimize collaboration between the various support
teams.
Next publication: 2016 annual sales
published January 12, 2017, after market.
About Medicrea (www.medicrea.com)
Medicrea specializes in the design, manufacture, and distribution of
innovative proprietary technologies devoted exclusively to spinal
surgery. Operating in a $10 billion market, Medicrea operates with 150
employees, including 40 at its Medicrea USA Corp. subsidiary based in
New York City.
Medicrea is the only company to offer personalized value-based
healthcare solutions to the global complex spine market. The Company has
driven innovation in Spine by focusing development on market-disrupting
technologies focused on patient outcomes, including the growing UNiD™
Technology Platform of Patient-Specific Implants and Analytical
Services, which received the first-ever FDA Clearance in November 2014
for a personalized spinal treatment modality.
Medicrea has uniquely positioned itself outside of the traditional
implant manufacturer’s role in order to engage with each market player
as a collaborator, offering customized implants to patients,
personalized services to doctors and immediate cost-savings to
providers. By leveraging its proprietary software analysis tools with
big data technologies, Medicrea is well-placed to improve the efficacy
of spinal care efficiency for all stakeholders in this market.

Connect with Medicrea:

FACEBOOK
| INSTAGRAM
| TWITTER
| WEBSITE
| YOUTUBE